Several collaborations with the line of connected devices
Nine months following its Initial public offering on the French stock market Alternext, Biocorp reported important progress with its portfolio of connected devices. The company announced several collaboration agreements with leading pharmaceutical players to develop Datapen and Easylog in the endocrinology and neurology fields. Although the company has yet to disclose more precisely for which indications they will be developed, this confirms the interest of pharmaceutical companies for Biocorp’s connected technologies. Biocorp also recorded strong growth on its historical activity, with sales increased by 49% in 2015 (€2.5M in 2015 vs €1.7M in 2014). The company’s objectives for the next months are to accelerate the R&D and business development programs, and scale up their manufacturing capabilities for their current industrial partnerships (Nipro, Nuova Ompi). We maintain our valuation on Biocorp with a target price of €17.59/share. Our valuation will be adjusted once we have more visibility on the collaboration agreements.
Biocorp Production SA is a France-based company, which is specialised in the development and manufacturing of medical and drug delivery devices.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.